Inotek May Be for Sale, But Who Will Buy?

Inotek May Be for Sale, But Who Will Buy?

With another failed trial of its glaucoma candidate trabodenoson in hand, Inotek Pharmaceuticals Corp. is pondering options that could include selling the company, but finding a buyer could be difficult. The dominoes started to fall in January, when Inotek reported that the trial of monotherapy trabodenoson did not achieve the results it was looking for.…

Read More

Encore Vision Delivers Big Payday to Angel Investors

Big winners in Novartis AG’s acquisition of Encore Vision for $465 million are members of a network of angel investors in Fort Worth, TX, that bet $4 million on the presbyopia-correcting eye drop that Encore Vision president and CEO Bill Burns has been working on for about nine years. The $4 million the Cowtown Angels…

Read More

Alcon Turnaround Has Novartis Exploring Spin-off

In announcing that Novartis AG is exploring spinning off its Alcon eye-care business, Novartis CEO Joseph Jimenez acknowledged that Alcon has made progress in the past year in executing its turnaround plan under CEO Mike Ball. Novartis revealed it is exploring options for Alcon that include spinning it off, issuing an IPO or keeping it,…

Read More

Shire’s Dempsey Shares Strategy to Building a Brand in Ophthalmology

On-Sight Interview: Shire’s Dempsey Shares Strategy to Building a Brand in Ophthalmology - OIS@ASCRS - Healthegy

Robert Dempsey, Vice President and Business Unit Head of Ophthalmology, Shire. See below for the Video Timestamp: 00:30 – How do you build a brand without a pipeline? 2:10 – Why did Shire choose to build in ophthalmology? 3:50 – Did Shire consider buying 5:15 – We are not dipping our toes in the water.…

Read More

Alcon Looking at looking at EDOF and IOL Technology

Michael Onuscheck, global surgical franchise head for Alcon, a Novartis company, outlined the firm’s approach to innovation within the premium channel, which involves both internal development and external partnerships and acquisitions. In this decade, the focus of cataract innovation has shifted from safety, efficacy, and efficiency/throughput to refractive outcomes and meeting patients’ expectations with respect…

Read More

Zeiss CEO Monz on Building a Really Strong Brand

[creativ_media type=”vimeo” url=”https://vimeo.com/168647895″] Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG, shares how his company’s long history in ophthalmology helps it pave a path for new markets and technologies. Video Highlights 00:34 – How much of Carl Zeiss is ophthalmology? 01:00 – In ophthalmology we try to provide everything needed for diagnosis…

Read More

Tom Frinzi’s Plans for AMO & Ophthalmology

Ophthalmology veteran Tom Frinzi joins OISTV to share his reasons for joining Abbott Medical Optics and what the company may be planning in coming years. Video Highlights 00:32 – What brought you to AMO? 1:20 – What are the three Ps? 2:02 – Is there a formula for leading any a company? 3:51 – How…

Read More

From Mythbuster to Dealmaker

Barry Cheskin, CEO, president and co-founder of PowerVision, provides details on his company’s new partnership with Alcon. Video Highlights: 00:30 – Details on Alcon deal including investment and opportunity to acquire. 01:08 – Combination will help bring Fluidvision 2020 to market even sooner. 01:19 – The Power of OIS 01:25 – Were you looking for…

Read More

Allergan Sees MIGS as “Ready to Explode”

Allergan purchased AqueSys (developer of the Xen Gel Stent) in a $20 million deal earlier this year. “Just a few years ago, the energy and excitement in ophthalmology was not in glaucoma,” said Dave LeCause, vice president, US eye care. Between 2010 and 2014, the US glaucoma market remained flat, but the introduction of micro-invasive…

Read More

Eye on Five – April Edition

OIS - Eye on Five

FDA Approves Avedro Corneal Collagen Cross-linking Platform The US Food and Drug Administration finally gave a green light to Avedro Inc. for its KXL System, a corneal collagen cross-linking platform for the treatment of progressive keratoconus. An FDA joint panel recommended approval in February last year, but a month later the agency denied approval, asking…

Read More

What are Allergan’s Next Steps?

What’s Allergan’s Next Steps? - OIS Podcast

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 081″] The near merger between Pfizer and Allergan clearly was financially motivated. But the deal promised to bring Pfizer’s firepower to ophthalmology. What does the annulment of the deal mean for our sector? Podcast Guest Brent Saunders Dr. Gil Kliman leads the medical device investment team at InterWest Partners and invests…

Read More

Without Pfizer Deal, Allergan Looks Ahead: Could B+L be in its Sights?

With Pfizer Deal, Allergan Looks Ahead: Could B+L Be In Its Sights? - Eye on Innovation

Now that Pfizer and Allergan have mutually agreed to terminate their proposed merger, Allergan CEO Brent Saunders told analysts Wednesday morning that the company is moving ahead with new product development, but he would not rule out the possibility of Allergan making a play for his old employer, Bausch + Lomb. The merger foundered when…

Read More